Tag Archives: CureVac fails in COVID-19 vaccine trial with 47% efficacy

German biotech CureVac said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union. The disappointing efficacy of the shot known as CVnCoV emerged from an interim analysis based on 134 COVID-19 cases in the …

Read More »